Business
SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2024 (Ended March 31, 2024)
SANUWAVE is pleased to announce preliminary revenues of $5.7 million to $5.9 million for the first quarter ended March 31, 2024. This represents the highest
About this update from Sanuwave Health, Inc.
[{"type":"text","content":"SANUWAVE is pleased to announce preliminary revenues of $5.7 million to $5.9 million for the first quarter ended March 31, 2024. This represents the highest Q1 revenues in company history.\nQ1 2024 revenue increased between 51% and 56% compared to Q1 2023.\nUltraMist revenues for Q1 2024 increased by more than 55% versus Q1 2023 and accounted for approximately 95% of the Company's total revenues.\nUltraMist applicator sales were an all time quarterly record and exceeded 65% of total revenues.\nEDEN PRAIRIE, MN - (NewMediaWire) - April 10, 2024 - SANUWAVE Health, Inc. (the \"Company\" or \"SANUWAVE\") (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the first quarter of 2024 are expected to be in the range of $5.7 to $5.9 million, an increase of 51% to 56% over Q1 2023 and consistent with the high end of the range of guidance given in the Company's Q4 2023 earnings release from March 22, 2024.\n\"As with much of the medical device and wound care industry, Q1 tends to be a seasonally softer quarter for SANUWAVE, but the underlying strength of our business has led to a smaller seasonal effect than that seen in recent years,\" said CEO Morgan Frank. \"This was the highest Q1 revenue in Company history by a wide margin, and the second best revenue quarter in Company history behind only Q4 2023. We're excited to report year-on-year revenue growth in excess of 50% for the quarter, a significant acceleration in growth versus prior quarters. The Company plans to release its full Q1 results in mid-May, and we look forward to speaking with you then to give you a more complete update on our quarterly performance and our future plans and guidance.\"\nThe preliminary revenue results described herein are based on management's initial analysis of the first quarter ended March 31, 2024, and may be subject to adjustments based on the Company's completion of its quarter-end financial close process.\nAbout SANUWAVE\nSANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.\nSANUWAVE's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the ...